Bottneuro AG develops and commercializes Miamind®, a personalized neuromodulation platform positioned in non-invasive brain stimulation for cognitive and neurological disorders. The company frames its approach around precision, patient-specific therapy planning and home-based deployment.

The system combines transcranial electrical stimulation (tES) with EEG capabilities and uses a custom-made cap with multiple electrodes to enable individualized montages. Personalization is described as being informed by patient-specific data and customized device manufacturing, with an emphasis on reproducible stimulation at home.

Use cases described by the company and third-party profiles include Alzheimer’s disease and other neurocognitive or neurological indications, with a clinical translation focus rather than consumer wellness. The product is presented as a regulated medical device pathway (including “custom-made medical device” positioning in EU-MDR contexts) and is marketed for home use within care pathways.